ArticleCancer discovery2020
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 156 citations in OpenAlex.
- A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.Frontiers in immunology · 2021Trial
- Structural and functional divergence of cancer hotspot mutations in CREBBP.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.Cell · 2026Article
- Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas.Research square · 2026Article
- TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through impairing nature killer cytotoxicity via the MYC-CD47/PD-L1 axis.Molecular cancer · 2026Article
- Novel therapeutic targets at the crossroad between epigenetics and signal transduction pathways in B-cell lymphomas.Clinical and experimental medicine · 2026Review
- Article
- Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma.Blood neoplasia · 2026Article
- Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.Blood advances · 2026Review
- Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review).International journal of molecular medicine · 2026Review
- Serpina3c protects against metabolic dysfunction-associated steatotic liver disease in offspring induced by prenatal prednisone exposure.Signal transduction and targeted therapy · 2026Article
- IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma.Blood cancer discovery · 2025Article
- Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.Blood · 2025Review
- Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Clinical epigenetics · 2025Article
- Article
- Unraveling the role of HDAC3 as an immunotherapy prognostic biomarker and therapeutic target in advanced non-small cell lung cancer.Respiratory research · 2025Article
- Recent advancements in double-expressor lymphoma: novel therapeutic approaches and prospects.The oncologist · 2025Review
- Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition.BMC cancer · 2025Article
- PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities.Clinical and experimental medicine · 2025Review
- Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 6 institutions in 2 countries.
Patrizia Mondello *Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.ORCID https://orcid.org/0000-0002-0355-3757
Saber Tadros *Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-2887-6122
Matt TeaterDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.ORCID https://orcid.org/0000-0001-9415-1659
Lorena FontanDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.ORCID https://orcid.org/0000-0002-1021-3654
Aaron Y ChangMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-7770-7405
Neeraj JainDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Haopeng YangDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shailbala SinghDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hsia-Yuan YingDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Chi-Shuen ChuLaboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York.
Man Chun John MaDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-2000-8144
Eneda ToskaDepartment of Human Oncology and Pathogenesis, Memorial Sloan Kettering Cancer Center, New York, New York.
Stefan AligDepartment of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.
Matthew DurantDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Sreejoyee GhoshDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Anja MottokInstitute of Pathology, University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Loretta NastoupilDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sattva S NeelapuDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Oliver WeigertDepartment of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-0987-7373
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
José BaselgaLaboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York.
Anas YounesDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Cassian YeeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-4429-7307
Ahmet DoganDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
David A ScheinbergMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert G RoederLaboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York.ORCID https://orcid.org/0000-0003-3865-8572
Ari M Melnick *Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York. mgreen5@mdanderson.org amm2014@med.cornell.edu.ORCID https://orcid.org/0000-0002-8074-2287
Michael R Green *Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. mgreen5@mdanderson.org amm2014@med.cornell.edu.
The University of Texas MD Anderson Cancer Center · USCornell University · USMemorial Sloan Kettering Cancer Center · USRockefeller University · USLudwig-Maximilians-Universität München · DEComprehensive Cancer Center Mainfranken · DE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MAnatomic Pathology Residency ProgramZIEBC011384 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BARR, FREDERIC · 2011 to 2025
$26.8MTranslating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ZELENETZ, ANDREW D. · 2016 to 2020
$10.9MPreclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI INGHIRAMI, GIORGIO · 2018 to 2022
$10.2MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MUnderstanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.R35CA241894 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID A SCHEINBERG · 2020 to 2026
$7.2MRECOMBINANT ANTICD33 ANTIBODY FOR AMLR01CA055349 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1991 to 2020
$6.8MIdentifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP InactivationR01CA201380 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Richard Green · 2016 to 2026
$3.5MTranscriptional regulatory mechanisms in B cell development and leukemogenesisR01CA178765 · NCI · ROCKEFELLER UNIVERSITY · PI ROEDER, ROBERT G · 2013 to 2017
$2.8MNCI NIH HHS P01 CA229100NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA055349NCI NIH HHS R01 CA178765NCI NIH HHS R01 CA201380NCI NIH HHS R35 CA241894NIH HHS U54 OD020355
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntigen-Presenting CellsAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCell Line, TumorCell ProliferationCREB-Binding ProteinCyclin-Dependent Kinase Inhibitor p21EpigenomeGenes, MHC Class IHistocompatibility Antigens Class IIHistone AcetyltransferasesHistone Deacetylase 3Histone Deacetylase InhibitorsHistone DeacetylasesHumansB7-H1 AntigenBCL6 protein, humanCDKN1A protein, humanCREB-Binding ProteinCREBBP protein, humanCyclin-Dependent Kinase Inhibitor p21Histocompatibility Antigens Class IIHistone AcetyltransferasesHistone Deacetylase 3Histone Deacetylase InhibitorsHistone DeacetylasesImmune Checkpoint InhibitorsInterferonsProto-Oncogene Proteins c-bcl-6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.